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Abstract
This study aims to characterize the mannose receptor (MR) gene in sheep and its role in ovine visna/maedi virus
(VMV) infection. The deduced amino acid sequence of ovine MR was compatible with a transmembrane protein
having a cysteine-rich ricin-type amino-terminal region, a fibronectin type II repeat, eight tandem C-type lectin
carbohydrate-recognition domains (CRD), a transmembrane region, and a cytoplasmic carboxy-terminal tail. The
ovine and bovine MR sequences were closer to each other compared to human or swine MR. Concanavalin A
(ConA) inhibited VMV productive infection, which was restored by mannan totally in ovine skin fibroblasts (OSF)
and partially in blood monocyte-derived macrophages (BMDM), suggesting the involvement of mannosylated
residues of the VMV ENV protein in the process. ConA impaired also syncytium formation in OSF transfected with
an ENV-encoding pN3-plasmid. MR transcripts were found in two common SRLV targets, BMDM and synovial
membrane (GSM) cells, but not in OSF. Viral infection of BMDM and especially GSM cells was inhibited by mannan,
strongly suggesting that in these cells the MR is an important route of infection involving VMV Env mannosylated
residues. Thus, at least three patterns of viral entry into SRLV-target cells can be proposed, involving mainly MR in
GSM cells (target in SRLV-induced arthritis), MR in addition to an alternative route in BMDM (target in SRLV
infections), and an alternative route excluding MR in OSF (target in cell culture). Different routes of SRLV infection
may thus coexist related to the involvement of MR differential expression.
Introduction
Visna/maedi virus (VMV) and caprine arthritis encepha-
litis virus (CAEV) belong to the small ruminant lenti-
virus (SRLV) group, within the non-oncogenic lentivirus
genus of the Retroviridae family, which includes the
human immunodeficiency virus (HIV), simian immuno-
deficiency virus (SIV), feline immunodeficiency virus
(FIV), bovine immunodeficiency virus (BIV) and equine
infectious anaemia virus (EIAV). Lentiviruses have been
classified attending to tropism into those that replicate
in macrophages and CD4 T lymphocytes (HIV, FIV,
BIV), leading to a decreased T cell number immunodefi-
ciency syndrome, and those that replicate in macro-
phages but are unable to infect T lymphocytes (SRLV
and EIAV). SRLVs infect sheep and goats, and cause,
after a variable asymptomatic period, a slow progressive
and invariably fatal disease affecting lungs, central ner-
vous system, carpal joints, and/or mammary gland [1,2].
Although different reports have described in vivo
infection in cells from mammary epithelium, third eye
lid, bone marrow, male reproductive tract, central ner-
vous system and carpal joints, the main target cells for
SRLVs in vivo appear to be the monocyte/macrophage
lineage. In vitro, viral production has been achieved in a
wide spectrum of cell types, synovial membrane and
choroid plexus cells being the most commonly used
[3,4]. Virus entry has been also detected in cells of het-
erologous origin such as 293-T human cell line but not
in Chinese hamster ovary (CHO) cells even under co-
culture conditions, likely due to the absence of a compa-
tible receptor as proposed previously [5]. Like other
enveloped viruses, SRLVs enter the host cell by interac-
tion of its envelope (ENV) glycosylated protein (gp135)
with cellular receptor(s), allowing the fusion of the virus
with the target cell membrane [6]. Studies aimed
to identify the SRLV cellular receptor have proposed
different candidate molecules, including a 30 kDa
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membrane-associated proteoglycan substituted with a
chondroitin sulphate glycosaminoglycan chain(s) [7];
MHC class II molecules, which incubated with VMV
inhibit viral infection, even though infection is not
inhibited by class II-specific antibodies [8]; CD4 and
CXCR4 molecules, which have been proposed as
optional auxiliary components of a VMV receptor (or
receptor complex) that facilitate VMV-mediated mem-
brane fusion events [9]; and a complex formed by three
membrane proteins of 15, 30 and 50 kDa identified as a
Visna binding protein [10]. Nevertheless, none of these
molecules has been established as the main essential
receptor, an issue which has stimulated research on
alternative candidates.
HIV infection of CD4 T cells has been impaired by
C-type lectins (such as Concanavalin A, ConA), whose
binding to carbohydrate molecules prevents cell fusion
and viral entry in culture due to the blockade of ENV
[11]. Other lectins anchored to the cell membrane
(C-type), such as the mannose receptor (MR) family
[12], have an affinity for the glycosylated moieties pre-
sent in the surface of many pathogens. The MR is pre-
sent in cells such as monocyte/macrophages, endothelial
cells, perivascular microglia, kidney mesangial cells
[13,14], tracheal smooth muscle cells [15], Langerhans
cells [16] and retinal pigment epithelium [17].
As described in humans, mice, swine and cattle,
[18-20], MR is a 180-kDa transmembrane protein with
five regions: a cysteine rich ricin-type amino-terminal
region, a fibronectin type II repeat, eight tandem C-type
lectin carbohydrate-recognition domains (CRD), a trans-
membrane region, and a cytoplasmic carboxy-terminal
tail. The CRD domains, and more specifically CRD4 and
CRD5 are essential to recognize mannose, fucose and
N-acetyl glucosamine residues. MR recognizes the sur-
face of pathogens and is involved in phagocytosis [14]
and endocytosis, mediating antigen processing and pre-
sentation, cell migration, intracellular signalling, and
pro-inflammatory and anti-inflammatory cytokine pro-
duction [21]. This receptor is able to bind bacteria,
yeast, parasites, and viruses, and links innate to acquired
immunity [22]. Blocking the macrophage MR with
ligands such as mannan or D-mannose leads to a
decreased HIV entry [23]. This study determines the
role of mannose-specific lectins on VMV infection and
syncytium formation and identifies the ovine MR and its
role as an alternative SRLV receptor.
Materials and methods
Viruses and cells
Primary cultures of ovine skin fibroblasts (OSF), ovine
choroid plexus (OCP) cells, goat synovial membrane
(GSM) cells, and goat choroid plexus (GCP) cells, were
obtained from SRLV-seronegative animals (tested by
ELITEST, Hyphen Biomed; Neuville-Sur-Oise, France)
and grown in DMEM medium supplemented with 10%
foetal bovine serum and 1% antibiotics/antimycotics mix
(Invitrogen, Barcelona, Spain). Chinese hamster ovary
(CHO) cells, known to be non-permissive to SRLV
infection [5], were grown in F-Ham 12 medium supple-
mented with 10% foetal bovine serum (Invitrogen).
CHO cells permanently transfected with murine MR
(kindly provided by Dr Luisa Martinez-Pomares, Univer-
sity of Nottingham, UK) [24] were maintained in F-Ham
12 medium with geneticin (0.5 mg/mL) and also used in
infection assays. Blood monocyte-derived macrophages
(BMDM) from SRLV-free sheep were obtained by cul-
turing peripheral blood mononuclear cells (PBMC) for
9-days in RPMI 1640 containing GlutaMAX™ I and
25 mM HEPES (Invitrogen) supplemented with 10% foe-
tal lamb serum (Invitrogen), 10 mM sodium pyruvate
(Invitrogen), 1% non-essential amino acids (Sigma,
Steinheim, Germany), 1% vitamins (Sigma), 50 μM
2-mercaptoetanol (Sigma), and granulocyte macrophage
colony-stimulating factor (GM-CSF; kindly provided by
Dr Gary Entrican, Moredun Institute, UK) at a concen-
tration of 10 ng/mL.
The EV1 strain [25] was used for in vitro VMV infec-
tion assays of BMDM, OSF and GSM cells. Strains EV1,
496 [26] and the infectious clone Kv1772 [27] were used
for in vitro infection of CHO and CHO-MR cells. All
the infections were performed using 0.1 TCID50/cell.
Amplification, cloning and sequencing of the ovine
mannose receptor
RNA was extracted from bronchoalveolar lavage cells of
a sheep with SRLV-induced interstitial pneumonia (146/
07), using TRIzol reagent (Invitrogen). The DNAse I
treated RNA was retrotranscribed to cDNA with Super-
Script II (Invitrogen), using oligo-dT as primers and fol-
lowing the manufacturer’s instructions. The cDNA
obtained was employed to perform overlapping poly-
merase chain reactions (PCRs). Primers were designed
on the highest homology regions among GenBank MR
sequences from human, swine and cattle origins. The
primer sequences and the amplicon lengths are shown
in Table 1. PCR was done using 600 nM final primer
concentration and an annealing temperature of 52°C.
For retrotranscription and RNA quality control, another
PCR was carried out using specific primers for the
amplification of a 106 nt fragment of the constitutively
expressed b-actin gene [28]. Following agarose gel elec-
trophoresis of PCR products, DNA was purified using
Gel/PCR extraction kit (ATP Biotech, Banciao, Taiwan)
and cloned into p-GEM-T Easy Vector System (Promega
Biotech Iberica, Madrid, Spain). The cloned product was
employed to transform electrocompetent Escherichia
coli XL1-Blue. Transformed bacteria were grown in LB
Crespo et al. Veterinary Research 2011, 42:28
http://www.veterinaryresearch.org/content/42/1/28
Page 2 of 10
Amp (100 μg/mL) in the presence of X-Gal (50 mg/mL)
and IPTG (50 mg/mL). The plasmid DNA was extracted
using the Plasmid Miniprep Kit (ATP Biotech). Once
the presence of the inserts in the plasmid was confirmed
by digestion with EcoRI and the plasmidic DNA from
three clones sequenced (Secugen, Madrid, Spain),
sequences were analyzed and assembled using the com-
puter software BioEdit, Chromas and MegaAlign. The
deduced amino acid sequence and the predicted protein
pattern were obtained with the ExPASy Proteomics
Tool [29].
Inhibition of viral infection in ConA treated cultures
To evaluate the effects of ConA on viral infection and
production, virus (strain EV1) was first preincubated for
60 min at 37°C either with ConA (50 μg/mL), ConA
and mannan (1 mg/mL), mannan or medium alone
before addition to the cell preparations. OSF and
BMDM in DMEM supplemented with 2% FBS or
macrophage medium, respectively, were incubated in
duplicated 24-well microplates for 1 h with the treated
or untreated virus inoculum. Wells were washed with
PBS to remove residual inoculum and medium contain-
ing lectin (ConA) and/or inhibitor (mannose-rich man-
nan) was added to a final volume of 1 mL per well.
Cells from one plate were collected 16 h post infection
(pi) and DNA extracted in order to quantify proviral
load. Supernatants from the second plate were collected
at day 7 pi, when cytopathic effect (syncytia) was evident
in untreated cell cultures (control). Experiments were
done in triplicate and repeated three times.
Luciferase assay
A luciferase assay was performed to ensure that Con-
canavalin A did not affect viral basal transcription and,
as a consequence, viral production. Briefly, 105 cells/
well in 24-well microplates were transfected at a ratio
of 1:8 (μg DNA: μL Lipofectamine) using the following
plasmids: pGL4.10 [luc2] (Promega) as negative con-
trol; pGL4.13 [luc2/SV40] (Promega), which contains
the SV40 promoter as positive control, and pGL4/U3-
KV1772 containing the LTR U3 region. Cells were co-
transfected with plasmid pRL-SV40 carrying the SV40
promoter and the Renilla reniformes luciferase gene as
an endogenous control of transfection and after 4 h
cells were treated with ConA, ConA and virus (EV1),
or medium alone. Following 24 h, cells were lysed with
Cell Culture Lysis Reagent 5 × (Promega) and lumines-
cence measured using the Dual-Glo™ Luciferase Assay
System (Promega). Luminescence units were normal-
ized to the total protein present in each sample, which
was quantified by the Bradford assay (BioRad, Madrid,
Spain). Firefly luciferase activity was normalized to
renilla luciferase activity. Results were expressed as
luciferase units/ng of the total protein of each sample.
Each experiment was done in triplicate and was
repeated three times.
Inhibition of syncitium formation by Concanavalin A in
env-transfected cultures
To test whether glycosylated ENV mediates cell fusion
allowing syncytium formation in the absence of virus,
ovine skin fibroblasts (OSF) were transfected with pN3-
env plasmid (pN3 with VMV env gene encoding the pre-
cursor protein gp150 [30]), using Lipofectamine (Invitro-
gen) at a ratio of 1:6 (DNA: Lipofectamine 2 mg/mL) and
following manufacturer’s instructions. ENV-containing
transformants were selected in the presence of geneticin
(0.5 mg/mL of medium). Empty plasmid (pN3) was used
as negative control. To determine the possible ConA-
mediated inhibitory effect, ConA (50 μg/mL) was added 5,
24 and 48 h following transfection. Syncytium formation
was evaluated by optical microscopy up to 72 h pi, after
Giemsa staining. Experiments were repeated twice.
Table 1 Oligonucleotide sequences used in the PCRs
performed in this study and amplicon length
PCR Oligonucleotides 5’- 3’ Amplicon
length
MR0 MR0Fw
CCATGAGGCTACCCCTGCTCCTGGTT
MR1Rv
GCGTACCACTTGTTTTCAAACTTG
560 nt
MR1 MR1Fw
CCGAATCTCAGATTATGAGTGTTGC
MR2Rv
CTTGCAGATGTAGCCAAGAGGCC
1253 nt
MR2 MR6Fw
GGCAAAGATGGATACTGGGCAG
CDR5Rv
CATTTGCAAAATTGGGTTCACC
1279 nt
MR3 CDR4Fw
GGCGAACCTAATAATTATCAG
MR7Rv
GTGCATCCAGGCAAAAGCATTAC
1210 nt
MR4 MR10Fw
ACAGGTGATCCCTCTGGTGAAAGA
MR10Rv
CTAGATGRCCRCATGTTCRTTCTG
408 nt
qMR
(CDR4-CDR5)
MR Fw
TGGCAAATCCAGTTGTTAAGATGTT
MR Rv
AGAATGTTGAATACTGTGGCGAGTT
91 nt
b-actin
(control)
Actin 663 Fw
CTCACGGAGCGTGGCTACA
Actin 769 Rv
GCCATCTCCTGCTCGAAGTC
106 nt
qPCR (p17
EV1)
MVV0262Fw
CTCCTTGCAGGCCACAATG
MVV0333Rv
GCTGCTTGCACTGTCTCGG
MVV0284P
6-FAM-TGCCTTATGTGTAGTCAGC-
TAMRA
71 nt
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Blocking of MR by mannan
Different concentrations of mannan (4, 2, 1, 0.5, 0.25
and 0.125 mg/mL) were administered to cultured OSF
(negative control), GSM cells and blood monocyte-
derived macrophages (BMDM, 105 cells/well in two 24-
well microplates). Following incubation (30 min at
37°C), the virus (Ev1) was added (0.1 TCID50/cell) and
cells were cultured for 16 h. After washing in PBS, one
plate was used for DNA extraction and provirus quanti-
fication (q-PCR). For RT activity determinations, the
second plate was further incubated until day 7, when
syncytia appeared in untreated cells. These blocking
experiments were repeated three times.
Real time PCRs
A real time PCR technique (q-PCR) was used to deter-
mine proviral DNA for quantifying viral entry-integra-
tion upon ConA and mannan treatments 16 h pi.
Briefly, OSF, GSM cells and BMDM (105 cells/well)
from the ConA and/or mannan experiments (see below)
were washed and fresh medium was added. Cells were
harvested and DNA extracted with Qiamp DNA Blood
Mini Kit (Qiagen, Hilden, Germany), according to the
manufacturer’s protocol. GAG (p17) segments were
quantified by q-PCR as described previously [28] using
ovine DNA from VMV infected cultures and oligonu-
cleotides reported in Table 1. Results were expressed as
provirus copy number/ng DNA. Tests were carried out
in duplicate and repeated three times.
Expression of MR was quantified using b-actin as a
housekeeping gene by substracting the corresponding
ΔCt value from that obtained in MR using cDNA from
BMDM, GSM, OSF, CHO or CHO-MR cultured cells.
Specific primers for amplification of the ovine b-actin
and the CDR4-CDR5 region of ovine MR are shown in
Table 1.
Reverse Transcriptase (RT) activity assay
RT activity was measured in cell culture supernatants
according to the manufacturer’s instructions (HS-Lenti
RT Activity kit, Cavidi, Uppsala, Sweden) as an indicator
of productive infection. The signal intensity thus
obtained was used to produce a standard curve in order
to quantify the virus, using as reference standard serial
dilutions of the same viral strain titrated by the classical
Reed-Muench method [31]. Experiments were done in
duplicate and repeated at least twice.
Western blot and ICC
OSF, CHO, CHO-MR and GSM cell lysates (40 μg)
were used in Western blot. A rabbit anti-human MR
polyclonal undiluted serum (cat. No. ab64693 Abcam,
Cambridge, UK) and two mouse anti-human MR mono-
clonal antibody reagents (clones 8 and 15. Personal
communication, Luisa Martinez-Pomares, University of
Nottingham, UK) were used as primary antibodies at a
dilution of 1/100. Anti-rabbit or anti-mouse (Thermo
Scientific, Erembodegem, Belgium) peroxidase-labelled
secondary antibodies were employed accordingly at a
dilution of 1/2000. The reaction was developed using
Supersignal West Pico Chemiluminiscent substrate
(Thermo Scientific). The same cells were also used fol-
lowing standard ICC protocols. Briefly, cells were
washed in PBS and fixed in methanol:acetone (1:1) for
5 min. In the case of BMDM, an additional peroxidase
blocking step was carried out using 5% H2O2 in metha-
nol for 5 min. Following washing, cells were blocked for
1 h using 2.5% casein and 5% lamb serum. Primary anti-
body was added undiluted (in the case of monoclonal
antibodies) or diluted in PBS containing 1.25% casein.
After washing, anti-rabbit or anti-mouse peroxidase-
labelled secondary antibodies were added at a 1/2000
dilution. The reaction was developed with diaminoben-
zidine (DAB).
Statistical analysis
The normal distribution of the data was confirmed by
Shapiro-Wilks and Kolmogorov-Smirnov tests. The
absorbance values between different treatments were
compared by Student’s t-test for related samples. Data
obtained from real time PCR were analysed by Wil-
coxon non-parametric test for related samples.
GenBank accession number
The assembled complete ovine MR sequence was sub-
mitted to GenBank and given accession number
HM099914.
Results
Characterization of the ovine mannose receptor (MR)
encoding sequence and comparison with other MRs
Taking into account the relevance of interaction of glyco-
sylated ENV with the soluble C-type lectin ConA on
VMV infection and cell fusion, we attempted the identifi-
cation of the gene encoding a cell surface-anchored
C-type lectin, the ovine MR, to determine subsequently
its possible role in VMV infection. Nucleotide sequence
analysis revealed that the complete ovine MR had a simi-
larity of 86 and 89% with the complete human and por-
cine MR, respectively. Bos taurus MR concatenated
sequence from GenBank, which included the amino-
terminal cysteine-rich domain, the fibronectin type-II
domain and seven of the eight known MR CDRs,
revealed the highest overall similarity (91%) with the
ovine counterpart. When comparing the similarity
between MR domains considered individually, CDR1,
CDR2, CDR4 and CRD5 were the most highly conserved
regions of MR across species (human, swine and ovine;
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Table 2). The deduced amino acid sequence of the ovine
MR presented the same structure as that of MR from
humans, swine or cattle: an extracellular region contain-
ing an amino-terminal cysteine-rich domain, a fibronec-
tin type-II domain, eight CRDs, a transmembrane region
and a short cytoplasmic tail. Both the ovine CDR4 and
CDR5 domains conserved a characteristic WND motif,
which has been reported to be a feature of the C-type lec-
tins [18]. The ovine sequence also conserved the FEN-
TLY and the di-aromatic Y-F motifs in the cytoplasmic
domain, FENTLY being relevant to the endocytic recep-
tor internalisation and di-aromatic Y-F motif being
involved in the endosomal sorting signal [32]. The pre-
dicted amino acid sequence of ovine MR had an identity
of 87% and 90% with MR of humans and swine,
respectively.
Presence of ovine MR transcripts
The presence of ovine MR transcripts was investigated
using MR CDR4-CDR5-specific RT-PCR in a panel of
cell types, including ovine GSM cells, BMDM and OSF
as well as CHO and CHO-MR cells, using b-actin as
endogenous expression control to confirm RNA quality.
PCR amplification and sequencing revealed that MR
transcripts were only found in GSM cells and BMDM
(Table 3). Since the ovine MR encoding sequence struc-
ture is compatible with a cell surface anchored protein,
as it occurs in other mammalian species, detection of
the ovine MR protein was attempted by WB and ICC
using three reagents (two monoclonal antibodies and a
polyclonal serum) to human MR. CHO cells transfected
with mouse MR were used as positive control. ICC
results always yielded unspecific perinuclear staining of
cells from ovine origin whereas in WB, monoclonal anti-
bodies to human MR failed to detect mouse MR (likely
due to the lack of cross-reactivity), whereas the polyclo-
nal serum against human MR detected only murine MR
on the CHO-MR cell surface which expression has been
previously shown [24]. Unfortunately, none of the three
reagents cross-reacted with the ovine MR expressed on
GSM cells or BMDM. Thus, ovine MR-specific antibody
inhibition experiments analogous to those carried out
with mannan could not be done, because antibodies
were unavailable.
Effect of the soluble lectin Concanavalin A on VMV
infection and syncytium formation
ConA is a cell-free lectin with a high capability of bind-
ing mannosylated residues able to inhibit HIV infection.
Since non-glycosylated VMV ENV does not allow cell
fusion, we determined if ConA could inhibit VMV infec-
tion and syncytium formation, and if this inhibition
diminished or disappeared upon addition of mannan.
For this purpose, the virus (VMV Ev1) was preincubated
with ConA and added to OSF and BMDM cultures. Pro-
viral load, determined 16 h after inoculation by q-PCR,
was decreased upon addition of VMV-ConA in OSF and
BMDM (P < 0.05; Figure 1A). Mannan partially, but sig-
nificantly, restored proviral load in cultures of OSF and
BMDM inoculated with ConA treated virus (P < 0.05;
Figure 1A). There was no RT activity in 16 h culture
supernatants (not shown), but 7 days pi, a highly signifi-
cant (P < 0.01) reduction of RT activity in both OSF
and BMDM (Figure 1B) infected with ConA treated
virus was observed. Preincubation of virus with ConA
and mannan completely restored RT activity in OSF cul-
ture supernatants (to values similar to those obtained in
OSF with untreated virus), and partially restored this
activity in BMDM culture supernatants. Preincubation
of virus with mannan alone did not cause any effect on
RT activity.
To exclude the possibility that ConA itself resulted
in decreased VMV LTR transcriptional activity (rather
than inhibiting viral entry), either ConA alone or
ConA and VMV (at the same concentrations as those
used in experiments corresponding to Figure 1) was
added to OSF cells transfected with the pGL4/U3-
KV1772 plasmid, which contained a LTR site driving a
luciferase gene reporter system. In this system, ConA
Table 2 Similarity values (%) between ovine MR
predicted amino-acid sequence with that from human,
swine and bovine species
Domain of ovine MR Species
Human Swine Bovine
Cystein rich domain 93.33 95.55 96.66
FN-II 91.67 90.00 96.66
CRD1 91.60 93.13 99.23
CRD2 90.48 93.88 98.63
CRD3 79.86 91.37 98.02
CRD4 94.74 96.05 99.28
CRD5 90.28 90.97 NA
CRD6 82.23 89.17 97.45
CRD7 78.95 83.46 93.98
CRD8 88.81 91.61 97.90
TM + cytoplasmic tail 76.77 80.81 96.96
FN-II: fibronectin type-II domain; CRD: carbohydrate recognition-like domain;
TM: transmembrane region. NA: sequence not available.
Table 3 Relative MR transcripts expression in different
cell types
Ct MR sd Ct b-actin sd ΔCt 100 × 2-ΔCt
BMDM 31.78 ± 0.08 28.58 ± 1.72 3.21 10.841646
GSM 36.16 ± 0.06 28.59 ± 0.04 7.57 0.526263
OSF 45.00 ND 18.46 ± 0.13 ND ND
CHO 45.00 ND 17.78 ± 1.71 ND ND
CHO-MR 31.32 ± 0.02 16.79 ± 0.64 14.53 0.004227
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either alone or combined with VMV did not cause any
inhibitory effect on LTR transcriptional activity (P >
0.05; Figure 2). Altogether, these results showed that
ConA inhibited VMV provirus integration into the cell
genome as well as productive infection, and that this
inhibitory effect was at least partially counteracted
with mannan.
Next, we determined if ConA affected syncytium for-
mation through its interaction with the VMV-ENV gly-
coprotein. For this, cells (OSF, easy to transfect) were
transfected with an ENV-encoding pN3-plasmid [30].
After 5 h, syncytia started to appear and cultures
showed thereafter an extended syncytium formation to
the end of the experimental period (72 h pi). Addition
of ConA to pN3-env transfected cultures after the 5-h
time point did not have any effect on the subsequent
appearance of syncytia. However, treatment with ConA
within 5 h after transfection inhibited syncytium forma-
tion 24, 48 or 72 h pi (Table 4). Thus, ConA impaired
syncytium formation, most likely by blocking mannosy-
lated residues of ENV.
Mannan blocking of VMV infection
Under the hypothesis that GSM cells and BMDM (and
not OSF) express MR on the cell membrane, we
assessed the role of MR in VMV infection using GSM
cells, BMDM, and OSF by a mannan-mediated blocking
approach.
The effect of mannan on VMV infection was studied
by determining proviral load in the three culture sys-
tems GSM cells, BMDM and OSF (Figure 3A) 16 h pi.
The addition of mannan resulted in a decreased proviral
copy number (about two fold) in GSM cells and BMDM
(P < 0.05), but it had no effect in OSF (P > 0.05).
Results compatible with these observations were
obtained when studying viral production (RT activity in
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Figure 2 LTR promoter activity in ovine skin fibroblasts (OSF).
OSF were transfected with pGL4/U3-KV1772 (clone containing VMV
LTR), pGL4.13 containing SV40 promoter (as positive control), or
pGL4 for basal activity (as negative control). Transfected cells were
treated with ConA, ConA and VMV or medium and the LTR activity
was measured 24 h pi using the Luciferase reporter system
(Promega). Firefly luciferase activity was normalized to renilla
luciferase activity. Data are expressed as luciferase units/ng total
protein of each sample. Values are the mean ± SE of assays
performed.
OSF
BMDM
Figure 1 Concanavalin A (ConA) mediated inhibition of visna/maedi (VMV) infection. Virus was preincubated with ConA, ConA-mannan or
mannan alone for 1 h and then used to infect ovine skin fibroblasts (OSF) and blood monocyte derived macrophages (BMDM). Inhibitory effects
of these treatments were measured by proviral load quantification (VMV copies per ng of DNA; A); and RT activity (absorbance at 405 nm) in
culture supernatants 7 days after inoculation (B). Values are the mean ± SE of the assays performed.
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culture supernatants) 7 days pi. About 4 and 2.5 fold
reduction in RT activity was observed in GSM cells (P <
0.0001) and BMDM (P < 0.05), respectively (Figure 3B).
The effect was dependent on mannan concentration,
decreasing beyond 2 mg/mL. Finally, the addition of
mannan to OSF cultures, even at high concentrations
(1-4 mg/mL), did not alter the production of virus (P >
0.05), as these cells were lacking MR transcripts, which
strongly suggests lack of MR protein.
Altogether, these results indicate that the ovine MR
was expressed in at least two cell types (GSM cells and
BMDM) susceptible to VMV infection, but not in OSF.
VMV infection via heterologous MR
In the absence of an ovine MR cell expression system,
CHO-MR (cells permanently expressing mouse MR
according to WB), and CHO cells (not expressing MR)
were infected with the VMV strains Ev1 [25], 496 [26]
and the infectious clone Kv1772 [27]. Uninfected CHO
and CHO-MR cells were used as control. VMV proviral
load was measured by q-PCR 16 h pi reaching 80.7 ± 9
copies/ng of DNA in the case of CHO-MR cells infected
with Ev1. After seven days of culture, RT activity in the
supernatants of all the CHO-MR cultures yielded posi-
tive values (Figure 4). Controls remained negative in
both tests. Syncytium formation was confirmed with
Giemsa staining in all cases. This culture supernatant
was also used to inoculate OSF cultures. Remarkably, no
RT activity was found 12, 21, 33 and 47 days pi, sug-
gesting that although CHO cells were permissive and
expressed heterologous (mouse) MR, they did not sup-
port VMV productive infection.
Table 4 Evaluation of syncytium formation by optical microscopy in pN3-Env and pN3 transfected OSF cells following
Concanavalin A addition at different time points
Syncytium formation evaluation
24 h 48 h 72 h
ConA addition time points (h)
5 - - -
pN3-ENV transfected OSF 24 + ++ ++++
48 + ++ ++++
5 - - -
pN3 transfected OSF 24 - - -
48 - - -
OSF
GSM cells
BMDM
Figure 3 Effect of mannan on VMV infection. Cell cultures of OSF, GSM cells and BMDM were pre-treated with mannan at different
concentrations for 30 min. Proviral load from DNA (A) and RT activity in the supernatant (B) of these cultures were determined 16 h and 7 days
pi respectively. Values are the mean ± SE of assays performed.
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Discussion
The role of innate immunity is gaining interest in the
field of lentiviral infections [33,34]. An important com-
ponent of innate immunity is the MR (CD206), a group
VI C-type lectin, present at the cell surface and endo-
somes [14]. This study identifies the ovine MR genetic
characteristics, the corresponding nucleotide and
deduced amino acid sequences and the putative protein
structure, all of which were found very close to those
found in other mammals [35,36]. Expression of the
ovine MR is being attempted at present through trans-
fection of SRLV non-permissive cells.
In the host, differences in MR oligomerization [37],
heterogeneity of MR N-glycosylation [38], as well as var-
iation in individual genetic makeup [39] and health sta-
tus [40] may account for differences in MR expression.
Like in other species, the ovine MR expression differed
among cell types, mRNA specific transcripts being pre-
sent in macrophages (BMDM) and synovial membrane
(GSM) cells, but not in skin fibroblasts (OSF). In SRLV
pathogenesis, GSM cells are known to be infected in
vivo [41] and if these cells do differentially express MR
on the cell surface in vivo as they do in vitro, MR could
represent an entry pathway of ENV-mannosylated
viruses through carpal joint infection.
The polyclonal reagent available to detect MR protein
expression was produced against a 57-amino acid pep-
tide of the human MR, but the limited size of this pep-
tide (about 3.9% of the whole MR protein) and
sequence differences (12 mismatches) between this
human MR peptide and the homologous peptide of
ovine origin may have led to the evident lack of cross-
reactivity of the polyclonal reagent with the ovine MR.
In contrast, this polyclonal antibody reacted with mouse
MR (with 16 mismatches in the peptide region com-
pared to human MR). The kind and site of amino acid
substitutions may account for the differences in cross-
reactivity of the polyconal reagent to the ovine vs. the
mice peptide.
Evidence of VMV infection in CHO cells transfected
with MR (from species like mice) supports the hypothesis
that MR expression is sufficient in vitro for VMV infection
in particular cell types. In a previous work [5] CHO/
mouse somatic cell hybrid lines became permissive to
SRLV if they included mouse chromosome 2 or 4. The
finding that mouse chromosome 2 contains the MR gene,
originally named Mcr in that species [42], may explain this
finding and suggests that the involvement of the mem-
brane associated C-type lectin DC-SIGN (dendritic
cell-specific ICAM-grabbing non-integrin) in this permis-
siveness (and not that of MR) could be excluded, since
DC-SIGN is encoded by chromosome 8 (and not chromo-
somes 2 or 4). Similarly in our study, the involvement of
DC-SIGN was unlikely, since dendritic cells were not
used. However, redundant or alternative pathways of virus
capture via lectins may coexist [43].
The observation that CHO cells become infected,
upon transfection with MR from species not susceptible
to VMV (mice), may indicate a non species-specific viral
interaction with the MR. However, the CHO-MR cells
infection by VMV was not productive, indicating that
subsequently to viral integration, factors involved in
viral production appear to differ when comparing CHO-
MR with GSM cells (expressing MR), the latter being
capable of productive infection.
There must be routes of virus entry into skin fibroblasts
(OSF) other than mannose binding lectins, as in these cells
blockade of infection by mannan did not take place but a
productive VMV infection was observed. Accordingly,
OSF appeared to bind, via a yet unidentified receptor dif-
ferent from MR, ENV viral protein glycosylated residues,
taking into account the need of ENV glycosylated residues
for cell fusion [38], and the observation that viral replica-
tion was strongly inhibited in these cells by ConA and
restored upon addition of mannan (likely by mannan bind-
ing to ConA). This ConA-mediated inhibition of virus
entry and syncytium formation is in agreement with
results in human cells using different carbohydrate-bind-
ing agents and HIV-1 strains [44].
The macrophages (BMDM) used in this study repre-
sent another category of cells, which express MR tran-
scripts but appear to produce at least two types of
VMV receptors, MR and an additional unknown recep-
tor. Mannan, when added to the virus preparation,
abrogated ConA effects but only partially in these
cells, according to RT activity and provirus quantifica-
tion. Furthermore, when mannan was added to the
cells, it inhibited infection (as it occurred in GSM
cells), but only partially. MR has been proposed in dif-
ferent species as a main virus binding site in particular
cells [45] (this might apply to GSM cells used in this
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Figure 4 SRLV infection of CHO cells expressing murine MR. RT
activity of CHO and CHO-MR cell cultures infected with the strains
EV1, 496 and KV1772 was determined (Absorbance 405 nm) in the
supernatants 7 days pi. Values are the mean ± SE of assays
performed.
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study) and/or an auxiliary molecule in other cells (this
would apply to BMDM employed in this work). In
non-phagocytic cells, MR is not acting as a profes-
sional phagocytic receptor, since it does not lead to
clearance of virus [46]. Accordingly, in our study the
VMV entry into GSM cells via MR subsequently led to
a productive infection. However in human cells such
as macrophages, results on significance of MR-
mediated HIV-1 endocytosis are inconclusive [45].
This may be due in part to the fact that lentiviruses
such as HIV-1 bind cells at least via two independent
pathways that may coexist in macrophages, the cur-
rently accepted infectious route by plasma membrane
protein receptors and the route mediated by the endo-
cytic MR, through which HIV-1 epitopes may be
subjected to exogenous MHC class I presentation
(cross-presentation) [23]. If this applies to the VMV
model, the second route would not be present in skin
fibroblasts (OSF), as they lacked MR transcripts and
were not susceptible to mannan-mediated blocking,
but would exist in GSM cells and BMDM.
However, caution should be taken when studying
MR expression in BMDM, as it may vary along the
individual’s life, having implications in pathogenesis.
Based on the macrophage phenotype classification in
subclinical vs. clinical stages [38] and according to this
and our previous studies [28], macrophages of SRLV
asymptomatic sheep (such as the BMDM tested in this
study) would exhibit increased B7 transcript produc-
tion, whereas those of clinically affected sheep would
be expected to have an increased MR expression and
viral infection. The known downregulation of B7 mole-
cule expression [28] and a Th2-biased antibody
response to the viral infection [47] occurring in VMV
clinical disease, including arthritis [26], would be com-
patible with an upregulation of MR expression in parti-
cular target organs such as carpal joints. Antibodies
against MR are currently being developed for immuno-
histochemical studies at different stages of VMV
infection.
Besides the cellular receptor, the genetic makeup of
the virus may determine the virus-cell interactions, since
the number and distribution of ENV amino acids sus-
ceptible to mannosylation, may affect viral entry through
membrane lectins and consequently the viral production
and appearance of disease. Further studies on ENV
composition and viral entry are warranted.
In conclusion, we report in vitro studies demonstrat-
ing that concerning viral entry there are at least three
main patterns in target cells capable of generating a pro-
ductive infection: i) particular cell types such as synovial
membrane (GSM) cells may use MR as a VMV main
infection route; ii) other cells such as fibroblasts (OSF)
use a route other than MR to bind the glycosylated
ENV allowing the virus entry to the cell; and iii) there
are cells like macrophages (BMDM), a classical SRLV
target, that use MR and an additional receptor for VMV
entry. The three cell types may be used as in vitro mod-
els to explore the mechanisms and relative relevance of
the different entry routes in VMV infections and pro-
vide the basis for studies in vivo, on tropism, viral
receptors and MR expression aimed to understand viral
pathogenesis and host progression from asymptomatic
to clinical stages.
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